Leadership at Avadel Pharmaceuticals

Gregory J. Divis was named Chief Executive Officer in June of 2019, after having served as Chief Operating Officer (named in March 2018) and Executive Vice President and Chief Commercial Officer (named in January 2017). Prior to joining Avadel, he served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. With over 25 years of experience in the pharmaceutical industry, Mr. Divis served as President and Chief Executive Officer of Lumara Health, a specialty branded pharmaceutical company focused on women’s health. Prior to Lumara, Mr. Divis held general management, sales, marketing and business development roles at Schering Plough and Sanofi-Aventis.

Jordan Dubow was appointed Chief Medical Officer in April 2019. Prior to joining Avadel, Dr. Dubow was employed from November 2018 until April 2019 by Esteve Pharmaceuticals, S.A., a pharmaceutical company headquartered in Barcelona, Spain, where he served as Vice President, CNS Therapeutic Strategy and was responsible for evaluating in-licensing candidates and provided regulatory and clinical support for Esteve’s entire development pipeline. From July 2016 until October 2018, Dr. Dubow was employed by Clintrex, a strategic advisory firm to the pharmaceutical industry, where he served as Vice President of Clinical & Medical Affairs, providing clinical, regulatory and business development support in the field of neurological diseases. From July 2015 until June 2016, Dr. Dubow was employed by Marathon Pharmaceuticals, a biopharmaceutical company focused on developing and commercializing therapies for neurological disorders, and served as Chief Medical Officer. Prior to Marathon Pharmaceuticals, Dr. Dubow was Vice President, Medical Affairs at Cynapsus Therapeutics, and Medical Director, Neuroscience Clinical Development at AbbVie. Dr. Dubow has both depth and breadth of experience in managing clinical development, medical affairs, business development and regulatory affairs, including multiple successful NDA submissions to the U.S. Food and Drug Administration, across a wide range of neurological diseases including sleep disorders such as narcolepsy. He is a board-certified neurologist who received his M.D. from the Northwestern University Feinberg School of Medicine. He has numerous peer-reviewed publications in neurological disorders and has served as a reviewer for various neurological journals.

Michael F. Kanan became Senior Vice President and Chief Financial Officer in October 2015. Prior to joining Avadel, Mr. Kanan was employed by Sigma-Aldrich Corp. from April 2009 until November 2015, where he served as Vice President Finance, Corporate Controller and Chief Accounting Officer of Sigma-Aldrich from April 2009 until November 2015. Sigma-Aldrich is a life science and high technology company which was acquired by Merck KGaA, a health care, life science and performance materials company based in Germany, in November 2015. Mr. Kanan began his career at the international accounting firm Deloitte & Touche, and also held accounting and finance leadership positions with Hutchinson Group, a subsidiary of Total S.A., and Meritor, a global supplier of drivetrain, mobility, braking and aftermarket solutions for commercial vehicle and industrial markets.

Phil Thompson has been a Senior Vice President and General Counsel since November 2013. Prior to joining Avadel, Mr. Thompson worked in a variety of legal roles at companies such as West-Ward Pharmaceutical Corp. and Paddock Laboratories, Inc. where he served as Vice President, Legal Affairs and Vice President, General Counsel, respectively. He has also held the role of Vice President, Strategic Business Transactions and Assistant General Counsel at KV Pharmaceutical Co, and as Associate General Counsel at Barr Laboratories, Inc. Mr. Thompson is a member of the New York Bar, the Missouri Bar, and the Minnesota Bar.

Sandra L. Hatten was appointed Senior Vice President of Quality and Regulatory Affairs in June 2015. Prior to joining Avadel, Ms. Hatten was employed from October 2010 to June 2015 by Mallinckrodt, plc, a global specialty biopharmaceutical company, where she served as Senior Vice President of Quality and Regulatory Compliance from February 2014 until June 2015. From October 2010 until September 2012, Ms. Hatten was employed by Mallinckrodt, as Director and Sr. Director of Quality. From September 2012 until February 2014, Ms. Hatten held the position of Vice President, Quality and Regulatory Compliance with Mallinckrodt. Ms. Hatten has more than 30 years of experience in the pharmaceutical industry, during which she has held leadership roles in quality and operations for brand as well as generic drug manufacturers, where she has been responsible for establishing and implementing broad-based quality programs across multiple sites.

David Monteith, Ph.D. was appointed Vice President of Research and Development in October 2014. Prior to joining Avadel, Dr. Monteith was employed from 2009 to 2014 at Merck & Co., Inc., a global healthcare solutions company, where he held the position of Associate Vice President of Pharmaceutical Development for Emerging Markets. From 2000 to 2009, Dr. Monteith was employed by Schering-Plough Corporation, a pharmaceutical company that merged with Merck & Co., Inc. in November 2009 in various positions from Associate Director, Pharmaceutical Development to Senior Director, Product Value Enhancement. With over 25 years of experience in the pharmaceutical industry, Dr. Monteith has held senior leadership roles in the areas of drug delivery and pharmaceutical drug product development.